Companies - Chemicals, Pharmaceuticals & Plastics - Australia

Refine my search:
Discover our Trusted Top Suppliers

Medibio Limited

Pharmaceuticals, Biotechnology & Life SciencesMedibio (ASX: MEB) (OTCQB: MDBIF), headquartered in Melbourne, Australia, with US headquarters in Minneapolis, Minnesota, is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes a panel of patented (and patent pending) circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental state. Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio is listed on the Australian Securities Exchange. and also trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Investors can find Real-Time quotes and market information for the company on and Pharmaceutical and Medicinal Product Manufacturing

  • Health, medical and pharmaceutical
  • Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
  • Pharmaceutical preparations for the cardiovascular system...
Back to top